All In Biotech

Drug Trial Radar · NCT05158777

Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old

A Randomized, Blind, Controlled Clinical Trial to Evaluate Safety and Immunogenicity of Live Attenuated Varicella Vaccine After a Two-dose Vaccination Course in Healthy Population Aged ≥13 Years Old

Last checked: Nov 19, 2026Latest source record: Dec 29, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,480 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,480

Actual

Start

Feb 13, 2022

Primary completion

Nov 14, 2022

Study completion Nov 14, 2022

Sponsor

Sponsor type
Industry
First posted
Dec 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 13 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a randomized, blind, controlled clinical trial of live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd. The purpose of this study is to evaluate the immunogenicity and safety of a two doses vaccination of investigational vaccine with 0,28 day and 0,56 day immunization schedule in population aged ≥13 years old.

Conditions

  • Varicella

Interventions

  • Live attenuated varicella vaccines manufactured by Shanghai Institute of Biological Products Co.,Ltd.Biological

    live varicella-zoster virus in 0.5 mL of sucrose, sodium chloride, potassium chloride, sodium glutamate, phosphate and injection water per injection

  • Live attenuated varicella vaccines manufactured by Changchun BCHT Biotechnology Co.,LtdBiological

    live varicella-zoster virus in 0.5 mL of mannitol, dextrose tincture, sucrose, trehalose, human serum albumin and injection water per injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Seroconversion rate of HI antibodyTime frame: Day 42 after the whole schedule
  2. GMT of HI antibodyTime frame: Day 42 after the whole schedule

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Henan Provincial Center for Disease Prevention and Control

    Zhenzhou, Henan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.